Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELLCOVORIN vs AMIKIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Rescue therapy after high-dose methotrexate therapy in osteosarcoma,Treatment of advanced colorectal cancer in combination with fluorouracil (off-label),To diminish toxicity and counteract effects of folic acid antagonists (e.g., trimethoprim, pyrimethamine) in certain infections
Treatment of serious gram-negative bacterial infections,Infections caused by susceptible strains of Pseudomonas aeruginosa, Escherichia coli, Proteus, Klebsiella, Serratia, and Enterobacter
WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
The terminal elimination half-life of folinic acid (active reduced folate) is approximately 6-7 hours in patients with normal renal function. The pharmacologically active metabolite, 5-methyltetrahydrofolate, has a longer half-life of about 10-12 hours. In renal impairment, half-life may be prolonged.
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Folinic acid is metabolized via reduction and methylation to active folate forms (e.g., 5-methyltetrahydrofolate) in the liver and other tissues. Involves dihydrofolate reductase and other folate-metabolizing enzymes.
Amikacin is not metabolized; it is excreted unchanged primarily by glomerular filtration.
Primarily renal excretion as unchanged drug and metabolites; about 80-90% of a dose is excreted in urine within 24 hours, with approximately 50-70% as unchanged folinic acid and the remainder as 5-methyltetrahydrofolate and other metabolites. Fecal excretion accounts for <10%.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Approximately 15% bound to plasma proteins, mainly albumin. Binding is not extensive.
0-10% (low binding to albumin).
Volume of distribution is approximately 0.5-0.6 L/kg, indicating distribution into total body water and some tissue binding. It crosses the blood-brain barrier poorly.
0.25 L/kg in adults; higher in neonates and edema states (0.3-0.4 L/kg), indicating distribution into extracellular fluid.
Oral bioavailability is variable: approximately 25-30% for the active isomer (l-folinic acid) due to first-pass metabolism; the racemic mixture (d,l-folinic acid) has a lower absolute bioavailability of about 30% for the active component. Intravenous and intramuscular routes provide 100% bioavailability.
IM: 100% (complete absorption); oral: <1% (not absorbed).
No specific GFR-based dose modifications are provided in the prescribing information. However, levoleucovorin is renally eliminated, and caution is advised in patients with renal impairment. For severe renal impairment (Cr Cl < 10 m L/min), consider dose reduction or extended interval. Monitor methotrexate levels and adjust leucovorin dose accordingly.
GFR 30-59 m L/min: extend dosing interval to every 12-24 hours; GFR 15-29 m L/min: extend to every 24-48 hours; GFR <15 m L/min: extend to every 48-72 hours or consider peritonitis dosing; adjust based on serum levels
No specific dose adjustments are recommended for hepatic impairment based on Child-Pugh class. However, caution is advised in patients with significant hepatic dysfunction due to potential altered folate metabolism.
No specific Child-Pugh based adjustments required; amikacin is minimally hepatically metabolized; monitor renal function as primary clearance route
WELLCOVORIN is not FDA approved for pediatric use. However, in pediatric patients, levoleucovorin is sometimes used at a dose of 10 mg/m² (or 0.2 mg/kg) every 6 hours for 5-7 doses, starting 24 hours after methotrexate infusion, adjusted based on methotrexate levels. Dosing should be individualized based on clinical response and methotrexate concentration.
Neonates: 15-20 mg/kg/day IV/IM every 12-24 hours depending on gestational age; Infants and children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day
No specific geriatric dose adjustments are recommended. Due to age-related decline in renal function, monitor renal function and methotrexate levels closely, and consider dose adjustment based on creatinine clearance.
Start with lower initial doses based on renal function; monitor renal function and serum amikacin levels closely; usual initial dose reduction to 7.5 mg/kg every 12-24 hours based on estimated GFR
No FDA black box warning.
Amikacin can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity (both vestibular and auditory) can occur in patients with pre-existing renal damage and in those with normal renal function treated with higher doses or for longer periods than recommended.
May mask pernicious anemia and other megaloblastic anemias due to vitamin B12 deficiency; caution in patients with renal impairment; hypersensitivity reactions; gastrointestinal toxicity with 5-FU combination.
Neurotoxicity (ototoxicity) and nephrotoxicity; neuromuscular blockade; respiratory paralysis; cross-allergenicity among aminoglycosides; monitoring of renal function and drug levels recommended.
History of severe hypersensitivity to folinic acid; pernicious anemia or other megaloblastic anemias secondary to vitamin B12 deficiency.
Hypersensitivity to amikacin or any aminoglycoside; history of ototoxicity with prior aminoglycoside use.
No significant food interactions have been reported. However, maintain adequate hydration and avoid alcohol due to potential hepatotoxicity. No specific dietary restrictions are required.
No significant food interactions. Maintain adequate hydration. Avoid alcohol as it may worsen side effects.
WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic acid antagonists. Available data do not indicate an increased risk of major birth defects with therapeutic doses. However, high-dose methotrexate therapy (which Wellcovorin is used to rescue from) is teratogenic. During first trimester, folate supplementation is protective against neural tube defects. During second and third trimester, folate requirements increase. No specific fetal risks are known from Wellcovorin alone. However, the underlying condition requiring treatment may pose risks.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicity, ototoxicity) at doses similar to or lower than human doses. Amikacin crosses the placenta. First trimester: Risk cannot be excluded; use only if clearly needed. Second and third trimesters: Potential for fetal nephrotoxicity and ototoxicity; avoid use unless necessary for serious infections. Risk category D (positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience).
Levoleucovorin is excreted into human milk. The M/P ratio is not established. Due to low molecular weight, excretion is expected. Exposure to the breastfed infant is likely low. Caution is advised. Use only if clearly needed.
Amikacin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. After intramuscular administration of 500 mg, peak milk concentrations are about 1-2 mcg/m L. Because of low oral bioavailability (poorly absorbed from the GI tract), systemic effects in the nursing infant are unlikely. However, theoretical risk of alteration of infant gut flora and direct exposure. Use with caution, especially in premature infants or those with renal impairment. The American Academy of Pediatrics considers amikacin compatible with breastfeeding.
Pregnancy increases folate clearance. Dose may need adjustment to maintain adequate serum folate levels, especially in high-dose methotrexate rescue. Monitor serum folate and adjust dose accordingly. Specific dose changes are not established; clinical judgment and monitoring are required.
Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, increased renal clearance) may require dose adjustments, but specific guidelines are not established. Generally, standard dosing based on actual body weight and renal function is used. Therapeutic drug monitoring is recommended, especially in third trimester or with concurrent renal impairment. Dose adjustments should be based on serum levels to maintain therapeutic efficacy while minimizing toxicity. No dose reduction is universally recommended; individualize based on renal function and clinical response.
WELLCOVORIN (levoleucovorin) is the active l-isomer of leucovorin; it does not require metabolic activation and is preferred in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. It is used to reduce the toxicity of methotrexate (MTX) and to enhance the efficacy of fluorouracil (5-FU). When used for MTX rescue, initiate 24 hours after start of MTX infusion; monitor serum MTX levels, creatinine, and urine p H. Rescue dose and duration depend on MTX levels; continue until MTX level < 0.05 μmol/L. For 5-FU modulation, administer immediately before or simultaneously with 5-FU; do not use with irinotecan due to increased diarrhea risk.
Monitor peak (20-30 mcg/m L) and trough (1-8 mcg/m L) serum levels; adjust dose based on renal function. Avoid concurrent use with other ototoxic/nephrotoxic drugs. Use extended-interval dosing (e.g., 15-20 mg/kg IV once daily) when possible. Assess for vestibular toxicity (ataxia, vertigo) and cochlear toxicity (tinnitus, high-frequency hearing loss).
Take this medication exactly as prescribed; do not change the dose or frequency without consulting your doctor.,This drug may be given as an injection or as an oral tablet; follow the instructions for the specific formulation you receive.,If you miss a dose, contact your healthcare provider; do not double the next dose.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or severe gastrointestinal symptoms (severe diarrhea, vomiting, abdominal pain) immediately.,Drink plenty of fluids to stay hydrated, especially during chemotherapy treatment.,Avoid alcohol while taking this medication as it may increase the risk of liver toxicity.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Report any hearing loss, ringing in ears, dizziness, or unsteadiness immediately.,Drink plenty of fluids to help prevent kidney damage.,Avoid taking other aminoglycosides or strong diuretics unless prescribed.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WELLCOVORIN vs AMIKIN, answered by our medical review team.
WELLCOVORIN is a Folic Acid Derivative that works by Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.. AMIKIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELLCOVORIN and AMIKIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELLCOVORIN is: WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.. The standard adult dose of AMIKIN is: 15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELLCOVORIN and AMIKIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELLCOVORIN is classified as Category C. WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic ac. AMIKIN is classified as Category C. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.